Examining Novel Therapies and Quality Improvement Initiatives for the Treatment of Heart Failure

Reserve your spot today for the Satellite Breakfast Symposium
Managed Care Review BoardTM - Examining Novel Therapies and Quality Improvement Initiatives for the Treatment of Heart Failure

Jointly provided by
Impact Education, LLC    
This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation.

Tuesday, October 4, 2016
6:00 AM - 7:45 AM
Gaylord National Hotel & Convention Center
Room: Maryland D
National Harbor, MD
Held in conjunction with

AMCP Nexus 2016
Please note: No additional fee is required to attend this CME/CPE activity; however, registration to AMCP Nexus 2016 is required.

Click here to download the slides from this symposium.

  • Clinical benefits of therapeutic decision-making in a new era of novel therapies
  • Integration of quality of care measures with plan-wide initiatives to improve outcomes and manage costs
  • Health economic and pharmacoeconomic assessment of emerging treatment options
  • Care coordination and member benefit strategies to enhance patient outcomes
Jeffrey Borer, MD
Professor of Medicine, Cell Biology, Radiology, and Surgery
Chief, Division of Cardiovascular Medicine
SUNY Downstate Medical Center
Adjunct Professor and Attending Physician, Cardiothoracic Surgery
Weill Medical College of Cornell University
Jeffrey Dunn, PharmD, MBA
Senior Vice President
Chief Clinical Officer
VRx Pharmacy Services, LLC
John Fox, MD, MHA
Senior Medical Director
Associate Vice President, Medical Affairs
Priority Health
Fadia Tohme-Shaya, PhD, MPH
Vice Chair for Academic Affairs PHSR
University of Maryland School of Pharmacy

This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, members of AMCP, and other managed health care professionals attending AMCP Nexus 2016.


Annually, >1 million patients are hospitalized with a primary diagnosis of heart failure (HF), and HF is the leading cause of hospitalization among adults >65 years of age in the United States. This HF-associated hospitalization represents a noteworthy driver of health care-related costs for managed care stakeholders, and serves as a surrogate marker for increasing mortality. Rehospitalization, despite dramatic improvement in outcomes with medical therapy, is also not uncommon: at least half of patients are readmitted to hospital within 6 months of discharge. This exemplifies a key area of interest for payers across all disease states, since reducing readmission rates also reduces costs and indicates an improvement in the quality of care.

The Managed Care Review BoardTM format features multi-specialty, multi-professional managed care, and clinical specialist faculty who collaborate on the review of the clinical data, current guidelines, and economic data of a specific class of therapeutics. It uniquely provides the audience with a review of important, relevant therapeutic category information and features peer-to-peer exchange between a diverse group of managed care and clinical specialist faculty contributors. This symposium is designed to engage the faculty and audience to develop solutions for managed care professionals to implement within their own setting to improve outcomes for patients with HF. This approach supports managed care pharmacists by enhancing the results of their own health care organization's systematic literature reviews and analyses.


At the conclusion of this activity, participants should be able to demonstrate improved ability to:
  • Describe the available efficacy and safety data for emerging therapies in heart failure (HF), including results from pivotal trials and evidence supporting averted HF-related hospitalizations and/or deaths
  • Apply appropriate positioning and utilization management criteria to facilitate judicious and effective utilization of emerging therapies for HF
  • Discuss available HF quality measures from nationally recognized governing bodies as well as from other health plans across the nation
  • Illustrate opportunities for HF quality improvement in health plan operations and infrastructure and implement measures to facilitate evidence-based prescribing and follow-up
  • Characterize the importance of addressing noncardiac comorbidities and overseeing care transitions as they pertain to maintaining therapeutic persistence and improving outcomes
  • Develop collaborative strategies for HF management enlisting the input and support of a multidisciplinary team of health care providers

Date and Time
Tuesday, October 4, 2016
6:00 AM - 7:45 AM
Gaylord National Hotel & Convention Center
Room: Maryland D
National Harbor, MD

6:00 AM Opening Comments and Pre-activity Assessment
6:05 AM Assessing the Clinical Benefits of Therapeutic Decision-Making in a New Era of Heart Failure Therapies
Jeffrey Borer, MD
6:30 AM Integration of Quality of Care Measures with Plan-Wide Initiatives to Improve Outcomes and Manage Costs
John Fox, MD, MHA
6:50 AM Faculty Idea Exchange
Faculty Panel
6:55 AM Health Economic and Pharmacoeconomic Assessment: Optimizing the Overall Value of Emerging Treatment Options
Fadia Tohme-Shaya, PhD, MPH
7:15 AM Care Coordination and Member Benefit Strategies to Enhance Patient Outcomes Across the Continuum of Heart Failure Management
Jeffrey Dunn, PharmD, MBA
7:35 AM Moderated Faculty Panel Discussion and Audience Q&A
Closing Comments
Post-activity Assessment and Evaluations
7:45 AM Adjournment
Physician Continuing Medical Education
Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources designates this live activity for a maximum of 1.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education
Accreditation Statement
Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
MER designates this continuing education activity for 1.75 contact hours (0.175 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - 0816-9999-16-076-L01-P

Type of Activity: Knowledge

Disclosure of Conflicts of Interest
It is the policy of Medical Education Resources to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Impact Education, LLC, prior to the live event at (215) 619-8812.

Fee Information
Please note: No additional fee is required to attend this CPE/CME activity; however, registration to AMCP Nexus 2016 is required.

Pre-registration will close at 12:00 pm on October 3, 2016.
Walk-in registration will be available at the time of the program.
If you have any questions, please call (215) 619-8812 or email info@impactedu.net.

Register Now